Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection

Expert Review of Anticancer Therapy

Volumn 4, Issue 3, 2004, Pages 401-410

  Hartmann, Pia ^a   Rehwald, Ute ^b   Salzberger, Bernd ^a   Franzen, Caspar ^a   Diehl, Volker ^c  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b PROvendis GmbH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Highly active antiretroviral therapy; HIV; HIV HL; Hodgkin's lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; CD4 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DIDANOSINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; PROTEINASE INHIBITOR; STAVUDINE; VINBLASTINE; VINCRISTINE; ZALCITABINE; ZIDOVUDINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CLINICAL FEATURE; DEATH; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; FEVER; GRAFT VERSUS HOST REACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; LYMPHADENOPATHY; NEUROLOGIC DISEASE; NEUTROPENIA; NIGHT SWEAT; OPPORTUNISTIC INFECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMOCYSTIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; STEM CELL MOBILIZATION; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 2942579351     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.3.401     Document Type: Review

References (91)

1. Levine AM. Hodgkin's disease in the setting of human immunodeficiency virus infection. J. Natl Cancer Inst. Monogr. 23, 37-42 (1998).
2. Franceschi S, Dal Maso L, Arniani S et al. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br. J. Cancer 78(7), 966-970 (1998).
3. Franceschi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms. Int. J. Cancer 83(4), 481-485 (1999).
4. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin. Oncol. 27(4), 390-401 (2000).
5. Goedert JJ, Cote TF, Virgo P et al. Spectrum of AIDS-associated malignant disorders. Lancet 351(9119), 1833-1839 (1998).
6. Grulich AE, Li Y, McDonald A et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. Aids 16(8), 1155-1161 (2002).
7. Grulich AE, Wan X, Law MG et al. Risk of cancer in people with AIDS. Aids 13(7), 839-843 (1999).
8. Frisch M, Biggar RJ, Engels EA et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA 285(13), 1736-1745 (2001).
9. Serraino D, Boschini A, Carrieri P et al. Cancer risk among men with, or at risk of, HIV infection in southern Europe. Aids 14(5), 553-559 (2000).
10. Petruckevitch A, Del Amo J, Phillips AN et al. Risk of cancer in patients with HIV disease. London African HIV/AIDS Study Group. Int. J. STD AIDS 10(1), 38-42 (1999).
11. Biggar RJ, Frisch M, Goedert JJ. Risk of cancer in children with AIDS. AIDS-Cancer Match Registry Study Group. JAMA 284(2), 205-209 (2000).
12. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N. Engl. J. Med. 338(13), 853-860 (1998).
13. Carrieri MP, Pradier C, Piselli P et al. Reduced incidence of Kaposi's sarcoma and of systemic non-Hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int. J. Cancer 103(1), 142-144 (2003).
14. Kirk O, Pedersen C, Cozzi-Lepri A et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 98(12), 3406-3412 (2001).
15. Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies: an international perspective. Hematol. Oncol. Clin. North Am. 17(3), 673-696 (2003).
16. Thirlwell C, Sarker D, Stebbing J et al. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clin. Lymphonza 4(2), 86-92 (2003).
17. Gabarre J, Bossi P. HAART and changes of epidemiology, treatment and prognosis of HIV-positive patients with Kaposi's sarcoma and lymphoma. Bull Cancer 90(5), 419-425 (2003).
18. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl Cancer Inst. 92(22), 1823-1830 (2000).
19. Gerard L, Galicier L, Boulanger E et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 17(1), 81-87 (2003).
20. Vilchez RA, Finch CJ, Jorgensen JL et al. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. Medicine (Baltimore) 82(2), 77-81 (2003).
21. Chiao EY, Krown SE. Update on non-acquired immunodeficiency syndrome-defining malignancies. Curr. Opin. Oncol. 15(5), 389-397 (2003).
22. Lukes RJ, Butler JJ, Hicks EB. Natural history of Hodgkin's disease as related to its pathological picture. Cancer 19, 317-344 (1966)
23. Lukes RJ, Craver RF, Hall TC et al. Report of the Nomenclature Committee. Cancer Res. 16, 1311 (1966).
24. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international Lymphoma Study Group. Blood 84(5), 1361-1392 (1994).
25. Andrieu JM, Toledano M, Raphael M et al. HIV-related hematological neoplasias in France. Recent Results Cancer Res. 112, 46-53 (1988).
26. Tirelli U, Errante D, Dolcetti R et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Co-operative Group on AIDS and Tumors. J. Clin. Oncol. 13(7), 17, 58-67 (1995).
27. Rubio R. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Co-operative Study Group of Malignancies Associated with HIV Infection of Madrid. Cancer 73(9), 2400-2407 (1994).
28. Ree HJ, Strauchen JA, Khan AA et al. Human immunodeficiency virus-associated Hodgkin's disease. Clinicopathologic studies of 24 cases and preponderance of mixed cellularity type characterized by the occurrence of fibrohistiocytoid stromal cells. Cancer 67(6), 1614-1621 (1991).
29. Bellas C, Santon A, Manzanal A et al. Pathological, immunological and molecular features of Hodgkin's disease associated with HIV infection. Comparison with ordinary Hodgkin's disease. Am. J. Surg. Pathol. 20(12), 1520-1524 (1996).
30. Boiocchi M, De Re V, Gloghini A et al. High incidence of monoclonal EBV episomes in Hodgkin's disease and anaplastic large-cell KI-1-positive lymphomas in HIV-1-positive patients. Int. J. Cancer 54(1), 53-59 (1993).
31. Carbone A, Tirelli U, Gloghini A et al. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J. Clin. Oncol. 11(9), 1674-1681 (1993).
32. Hamilton-Dutoit SJ, Pallesen G, Karkov J et al. Identification of EBV DNA in tumour cells of AIDS-related lymphomas by in situ hybridisation. Lancet 1(8637), 554-552 (1989).
33. Herndier BG, Sanchez HC, Chang KL et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease. Am. J. Pathol. 142(4), 1073-1079 (1993).
34. Carbone A, Dolcetti R, Gloghini A et al. Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study. Hum. Pathol. 27(2), 133-146 (1996).
35. Carbone A, Gloghini A, Volpe R et al. High frequency of Epstein-Barr virus latent membrane protein-1 expression in acquired immunodeficiency syndrome-related Ki-1 (CD30)-positive anaplastic large-cell lymphomas. Italian Co-operative Group on AIDS and Tumors. Am. J. Clin. Pathol. 101(6), 768-772 (1994).
36. Gaidano G, Carbone A. AIDS-related lymphomas: from pathogenesis to pathology. Br. J. Haematol. 90(2), 235-243 (1995).
37. Carbone A, Gloghini A, Larocca LM et al. Human immunodeficiency virus-associated Hodgkin's disease derives from postgerminal center B-cells. Blood 93(7), 2319-2326 (1999).
38. Andrieu JM, Roithmann S, Tourani JM et al. Hodgkin's disease during HIV1 infection: the French registry experience. French Registry of HIV-associated Tumors. Ann. Oncol. 4(8), 635-641 (1993).
39. Ames ED, Conjalka MS, Goldberg AF et al. Hodgkin's disease and AIDS. Twenty-three new cases and a review of the literature. Hematol. Oncol. Clin. North Am. 5(2), 343-356 (1991).
40. Lowenthal DA, Straus DJ, Campbell SW et al. AIDS-related lymphoid neoplasia. The Memorial Hospital experience. Cancer 61(11), 2325-2337 (1988).
41. Knowles DM, Chamulak GA, Subar M et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986). Ann. Intern. Med. 108(5), 744-753 (1988).
42. Karcher DS. Clinically unsuspected Hodgkin disease presenting initially in the bone marrow of patients infected with the human immunodeficiency virus. Cancer 71(4), 1235-1238 (1993).
43. Tirelli U, Errante D, Vaccher E et al. Hodgkin's disease in 92 patients with HIV infection: the Italian experience. GICAT (Italian Co-operative Group on AIDS & Tumors). Ann. Oncol. 3(Suppl.), 469-472 (1992).
44. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N. Engl. J. Med. 339(21),1506-1514 (1998).
45. Spina M, Re A, Vaccher E et al. High international prognostic score predicts a worse outcome for patients with Hodgkin's disease and HIV infection: results of a prospective study with Stanford V regimen. Ann. Oncol. 14(4), 655-656 (2003).
46. Errante D, Tirelli U, Gastaldi R et al. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Co-operative Group on AIDS and Tumors (GICAT). Cancer 73(2), 437-444 (1994).
47. Errante D, Gabarre J, Ridolfo AL et al. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann. Oncol. 10(2), 189-195 (1999).
48. Levine AM, Li P, Cheung T et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J. Acquir. Immune Defic. Syndr. 24(5), 444-450 (2000).
49. Diehl V, Franklin J, Hasenclever D et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J. Clin. Oncol. 16(12), 3810-3821 (1998).
50. Diehl V, Franklin J, Hasenclever D et al. BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann. Oncol. 9(Suppl. 5), S67-S71 (1998).
51. Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J. Clin. Oncol. 20(3), 630-637 (2002).
52. Spina M, Gabarre J, Rossi G et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 100(6), 1984-1988 (2002).
53. Hartmann P, Rehwald U, Salzberger B et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann. Oncol. 14(10), 1562-1569 (2003).
54. Mocroft A, Katlama C, Johnson AM et al. AIDS across Europe, 1994-1998: the EuroSIDA study. Lancet 356(9226), 291-296 (2000).
55. Ledergerber B, Egger M, Erard V et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 282(23), 2220-2226 (1999).
56. Jones JL, Hanson DL, Dworkin MS et al. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. J. Acquir. Immune Defic. Syndr. 21 (Suppl. 1), S11-S17 (1999).
57. Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 15(12), 1483-1491 (2001).
58. Baiocchi OC, Colleoni GW, Navajas EV et al. Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma. Acta Oncol. 41(2), 192-196 (2002).
59. Chow KU, Mitrou PS, Geduldig K et al. Changing incidence and survival in patients with AIDS-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk. Lymphoma 41(1-2), 105-116 (2001).
60. Hoffmann C, Wolf E, Farkenheuer G et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 17(10), 1521-1529 (2003).
61. Navarro JT, Ribera JM, Oriol A et al. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma. Leuk. Lymphoma 43(9), 1837-1842 (2002).
62. Navarro JT, Ribera JM, Oriol A et al. Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 32(3), 347-348 (2003).
63. Navarro JT, Ribera JM, Oriol A et al. Influence of highly active antiretroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br. J. Haematol. 112(4), 909-915 (2001).
64. Little RF, Yarchoan R, Wilson WH. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. Curr. Opin. Oncol. 12(5),438-444 (2000).
65. Vaccher E, Spina M, di Gennaro G et al. Concomitant cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 91(1), 155-163 (2001).
66. Tam HK, Zhang ZF, Jacobson LP et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int. J. Cancer 98(6), 916-922 (2002).
67. Simonelli C, Zanussi S, Cinelli R et al. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. Clin. Infect. Dis. 37(6), 820-827 (2003).
68. Ribera JM, Navarro JT, Oriol A et al. Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. AIDS 16(14), 1973-1976 (2002).
69. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann. Intern. Med. 64(2), 328-340 (1966).
70. Bronchud MH, Potter MR, Morgenstern G et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br. J. Cancer 58(1), 64-69 (1988).
71. Esser M, Brunner H. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics 2108), 1295-1313 (2003).
72. Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 23(8 Pt 2), 15S-19S (2003).
73. Carey PJ. Drug-induced myelosuppression: diagnosis and management. Drug Saf. 26(10), 691-706 (2003).
74. Hubel K, Engert A. Clinical applications of granulocyte colony-stimulanng factor: an update and summary. Ann. Hematol. 82(4), 207-213 (2003).
75. Bohlius J, Reiser M, Schwarzer G et al. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br. J. Haematol. 122(3), 413-423 (2003).
76. Ratner L, Lee J, Tang S et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J. Clin. Oncol. 19(8), 2171-2178 (2001).
77. Nielsen SD, Sorensen TU, Aladdin H et al. The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals. Scand. J. Immunol. 52(3), 298-303 (2000).
78. Kuritzkes DR. Neutropenia, neutrophil dysfunction and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin. Infect. Dis. 30(2), 256-260 (2000).
79. Armstrong WS, Kazanjian P. Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin and interleukin-2. Clin. Infect. Dis. 32(5), 766-773 (2001).
80. Tirelli U, Vaccher E. Economic and clinical evaluation of therapy of HIV-related non- Hodgkin's lymphoma with chemotherapy and granulocyte colony-stimulating factor (G-CSF). Eur. J. Cancer 30A(10), 1589-1590 (1994).
81. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomes de l'Adulte study. J. Clin. Oncol. 18(16), 3025-3030 (2000).
82. Zinzani PL, Tani M, Gabriele A et al. High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience. Haematologica 88(5), 522-528 (2003).
83. Re A, Cattaneo, C, Michieli M et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J. Clin. Oncol. 21(23), 4423-4427 (2003).
84. Molina A, Zaia J, Krishnan A. Treatment of human immunodeficiency virus-related lymphoma with haematopoietic stem cell transplantation. Blood Rev. 17(4), 249-258 (2003).
85. Krishnan A, Zaia J, Forman SJ. Should HIV-positive patients with lymphoma be offered stem cell transplants? Bone Marrow Transplant. 32(8), 741-748 (2003).
86. Gabarre J, Azar N, Autran B et al. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 355(9209), 1071-1072 (2000).
87. Kolb HJ, Mittermuller J, Clemm. C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12), 2462-2465 (1990).
88. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82(8), 2310-2318 (1993).
89. Bar BM, Schattenberg A, Mensink EJ et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J. Clin. Oncol. 11 (3), 513-519 (1993).
90. Kang EM, de Witte M, Malech H et al. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood 99(2), 698-701 (2002).
91. Tirelli U, Bernardi D. Impact of HAART on the clinical management of AIDS-related cancers. Eur. J. Cancer 37(10), 1320-1324 (2001).